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It is now established that bone marrow–derived my-
eloid cells regulate tumor angiogenesis. This was orig-
inally inferred from studies of human tumor biopsies
in which a positive correlation was seen between the
number of tumor-infiltrating myeloid cells, such as
macrophages and neutrophils, and tumor microves-
sel density. However, unequivocal evidence was only
provided once mouse models were used to examine
the effects on tumor angiogenesis by genetically or
pharmacologically targeting myeloid cells. Since
then, identifying the exact myeloid cell types in-
volved in this process has proved challenging because
of myeloid cell heterogeneity and the expression of
overlapping phenotypic markers in tumors. As a
result , investigators often simply refer to them now
as “bone marrow–derived myeloid cells.” Here we
review the findings of various attempts to pheno-
type the myeloid cells involved and discuss the
therapeutic implications of correctly identifying—
and thus being able to target—this proangiogenic
force in tumors. (Am J Pathol 2010, 176:1564–1576; DOI:
10.2353/ajpath.2010.090786)
There is now compelling evidence that bone marrow–
derived cells (BMDCs) play an important role in regulat-
ing angiogenesis during tumor progression and recovery
after antiangiogenic or cytotoxic therapy. Myeloid-lin-
eage BMDCs shown to be ‘proangiogenic’ in mouse
tumor studies include monocytes/macrophages,1–7
dendritic cell (DC) precursors,8,9 mast cells,10,11 neu-
trophils,12–14 and the so-called ‘myeloid-derived sup-
pressor cells’ (MDSCs, or CD11bGr-1 cells).15–17
Such cells (see Table 12,3,5,9,15,16,18–31 for a glossary)
are thought to promote angiogenesis in tumors largely
by expressing factors that promote the growth and
expansion of new blood vessels from the pre-existing
vasculature - either by the direct stimulation of endo-
thelial cells (ECs) or the remodeling of the extra-
cellular matrix (reviewed in 32–37).
As will be seen, various experimental approaches
have been used in mice to define the role of myeloid cells
in tumor angiogenesis including their genetic manipula-
tion or pharmacological targeting, sometimes in combi-
nation with BM transplantation (BMT). However, identify-
ing the exact myeloid cell types involved in tumor
angiogenesis is proving increasingly difficult, not only
because considerable heterogeneity and functional re-
dundancy exist among tumor-infiltrating myeloid cells,
but also because these cell types often express overlap-
ping phenotypic markers (Figure 1). In this review, we
discuss the advantages and limitations of using different
techniques and various markers to identify myeloid cells
implicated in tumor angiogenesis as well as evaluate
what they tell us about the identity and function of the
cells involved.
In addition to ‘classic’ myeloid cells, other BMDCs
have been implicated in tumor angiogenesis. These
include various progenitor or precursor cell popula-
tions, such as hematopoietic stem/progenitor cells (HS/
PCs),38,39 endothelial progenitor cells (EPCs),6,38,40–44
pericyte precursor cells,2,45,46 and mesenchymal stem/
stromal cells.47,48 The many unresolved issues related to
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the phenotypic and functional identification of some of
these progenitor/precursor cells—EPCs, in particular—in
the context of tumor angiogenesis have stimulated a
long-standing lively debate in the vascular biology field
(reviewed in 33,49–53). The functional importance of
EPCs in tumor angiogenesis has been discussed else-
where (see references above) and is beyond the remit of
this article.
Table 1. A Glossary for BMDCs Implicated in Tumor Angiogenesis
Definition
(alphabetic order) Description
References
(selected)
CD11b Gr-1 cells CD11b and Gr-1 are cell surface markers broadly expressed by myeloid-lineage cells.
The combination of such markers is commonly used to identify a myeloid cell population
that expands in the bone marrow, blood, and spleen of tumor-bearing mice. The
CD11bGr-1 cells comprise both monocyte- and granulocyte-lineage cells and are
also referred to as myeloid-derived suppressor cells (MDSCs). In tumors, CD11bGr-1
cells are less abundant than classic macrophages (which are Gr-1) and mostly
comprise neutrophils and inflammatory monocytes. CD11bGr-1 cells/MDSCs are
thought to promote tumor progression mainly through immunosuppression; however,
subsets of these cells—neutrophils in particular—may also promote angiogenesis via
both VEGF-dependent and independent pathways.
15,16,18,19
Inflammatory
monocytes
In the mouse, circulating monocytes can be separated into at least two main subsets:
inflammatory (or classic) and resident monocytes. Inflammatory monocytes are
considered the precursors of macrophages and dendritic cells recruited to inflamed
tissues (including tumors); they express Ly6C and CCR2, the receptor for CCL2 (also
known as monocyte chemoattractant protein-1, MCP-1). Once recruited to tumors,
inflammatory monocytes are thought to differentiate into tumor-associated macrophages
(TAMs).
20–22
Hemangiocytes The term “hemangiocyte” was coined by Rafii and coworkers to designate a population of
hematopoietic progenitors that express CD11b, VEGFR-1, CXCR4, Sca1, and Tie2. The
relationship between these hemangiocytes and other hematopoietic progenitors or
differentiated myeloid-lineage cells (such as monocytes, TEMs in particular) requires
further investigation. VEGFR-1 hemangiocytes and Tie2 monocytes appear to be a
major source of functional MMP9 in tumors.
2
M1 or classic
macrophage
activation
In response to microbial agents and Th1 cytokines such as interferon-, macrophages
undergo an activation program referred to as “classic,” or “M1” activation. Classically
activated macrophages are potent effector cells that can kill microorganisms and tumor
cells and produce copious amounts of proinflammatory cytokines. In vitro–polarized M1
macrophages express high amounts of the antiangiogenic cytokines IL-12, CXCL9, and
CXCL10.
23,24
M2 or alternative
macrophage
activation
Available information suggests that several tumor- and T cell–derived cytokines, such as
IL-4, IL-13, IL-10, as well as glucocorticoid hormones and vitamin D3, can induce TAMs
to undergo an “alternative” or “M2” activation program. M2-polarized macrophages
produce a variety of growth factors that regulate tumor-cell proliferation and invasion,
angiogenesis, and the deposition and dissolution of connective tissues. These include
epidermal growth factor (EGF), members of the fibroblast growth factor (FGF) and
vascular endothelial growth factor (VEGF) families, and transforming growth factor-
(TGF-). It is generally believed that M2-polarized macrophages have a key role in
promoting tumor growth and progression and subverting antitumor immunity. It is likely
that fully polarized M1 and M2 macrophages are the extremes of a continuum of
phenotypes variably expressed in different tumor microenvironments (see Figure 2).
19,23,24
MDSCs (myeloid-
derived
suppressor cells)
See CD11b Gr-1 cells.
Resident monocytes Circulating resident monocytes are a monocyte subpopulation distinct from inflammatory
monocytes. Resident monocytes, which are Ly6C and CCR2, patrol blood vessels
and may differentiate into proangiogenic macrophages once extravasated at sites of
tissue injury or ischemia. TEMs appear to be a subpopulation of resident monocytes;
the role of resident monocytes in tumors is otherwise very poorly known.
20–22
TEMs (Tie2-
expressing
monocytes/
macrophages)
TEMs express the angiopoietin receptor Tie2, a feature that distinguishes them from other
monocytes/myeloid cells. TEMs circulate both in human and mouse peripheral blood
and are recruited to sites of tissue remodeling, including tumors, where they appear to
provide paracrine support to angiogenesis.
5,25–27
TAMs (tumor-
associated
macrophages)
TAMs are thought to derive from circulating inflammatory monocytes. F4/80 TAMs make
up a major proportion of the CD11b myeloid cells found in a variety of mouse tumor
models. Defined factors present in the tumor microenvironment can induce TAMs to
acquire distinct activation states (see M1 and M2 activation). In progressing tumors,
TAMs are largely M2-polarized and produce a wide array of proangiogenic factors.
3,28,29
Vascular leukocytes These cells represent a population of proangiogenic monocytes that coexpress myeloid
(eg, CD11b) and EC markers (eg, VE-Cadherin and Tie2). Vascular leukocytes are
particularly abundant in human ovarian cancers but are also detected in a number of
murine tumors. Recently, vascular leukocytes have been shown to phenotypically
overlap with TEMs.
9,30,31
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Myeloid Cells Implicated in Tumor Angiogenesis
Monocytes/Macrophages
These cells are released from the bone marrow as
promonocytes, mature into monocytes in the circula-
tion, infiltrate tumors, and differentiate further into tu-
mor-associated macrophages (TAMs).23,28 Once resi-
dent in tumors, macrophages express a wide array of
proangiogenic factors, including vascular endothelial
growth factor (VEGF)-A and matrix metalloproteinase
(MMP)9.12,54,55 Evidence for their role in tumor angio-
genesis has been established by several different exper-
imental approaches. First, the combination of human
macrophages and small avascular human tumor nodules
implanted into a murine skinfold window chamber assay
results in a significant increase in new blood vessels
when compared with tumor nodules containing no mac-
rophages.7 By using MMTV-PyMT mammary tumor-prone
mice carrying a colony stimulating factor-1 (Csf1) null
mutation (Csf1op/op), Lin and co-workers3,4 demonstrated
that the absence of CSF-1 markedly decreased macro-
phage infiltration in pre-malignant tumors, and this, in
turn, resulted in inhibition of tumor angiogenesis and
delayed metastasis. Furthermore, inhibition of tumor-de-
rived TAM chemoattractants, ablation of TAMs by DNA
vaccination, or pharmacological neutralization of TAM-
produced proangiogenic molecules also impaired tumor
angiogenesis in various tumor models.56–58 It should be
noted, however, that in Ccr2-deficient, K14-HPV cervical
tumor-prone mice, the genetic depletion of TAMs un-
leashed a compensatory neutrophil response that res-
cued tumor angiogenesis and progression.14 This inter-
esting observation highlights that a certain degree of
functional redundancy exists among tumor-infiltrating
proangiogenic myeloid cells and that this may vary in a
tissue- or organ-specific fashion.
TAM depletion from tumors removes each of the many
aspects of macrophage involvement from tumor progres-
sion. These include, in addition to the production of
VEGF-A and other proangiogenic factors, the release of
cellular mediators that promote immunosuppression
and enhance tumor cell survival, migration, and inva-
sion.23,28,29,59 To specifically analyze the role of myeloid
cell–derived VEGF-A in tumor angiogenesis, Stockmann
and coworkers60 crossed mice carrying loxP-flanked
Vegfa alleles to mice carrying a lysozyme M (LysM) pro-
moter-driven Cre recombinase. Interestingly, the authors
found that the targeted deletion of VEGF-A in myeloid
cells failed to inhibit angiogenesis and tumor growth or
decrease the overall amount of VEGF-A expressed in
tumors. Rather, it attenuated the vascular abnormalities
commonly observed in tumors and improved tumor per-
fusion (a phenomenon previously referred to as ‘vascular
normalization’61). These results suggest that VEGF-A pro-
duction by TAMs promotes the formation of chaotic,
poorly functional tumor-associated vasculature—at least
in the murine tumor models used.
As defined here, TAMs comprise distinct macrophage
subpopulations. Egeblad and coworkers62 developed
and applied multicolor imaging techniques (reviewed in
63) to analyze the recruitment and behavior of macro-
phages and related myeloid cells in different tumor mi-
croenvironments in live mice. MMTV-PyMT mice were
crossed with a transgenic mouse line expressing GFP
under the control of the promoter of the Csf1r gene, which
is specifically expressed in monocyte/macrophage-lin-
eage cells. The movement of GFP cells within tumors
was then visualized along with fluorescently labeled dex-
tran (to label blood vessels and macrophages that engulf
dextran) and fluorescently labeled monoclonal antibod-
ies (to better identify the myeloid cell subsets involved).
Based on their motility, expression of surface markers
(such as mannose receptor-1, Mrc1/CD206), and ability
to phagocytize dextran, the macrophages could be clas-
sified into distinct subpopulations, including low-migra-
tory Mrc1/dextran macrophages, which are found in
the peritumor areas, and sessile Mrc1–/dextran– macro-
phages, which are found within the tumor mass.62 This
real-time analysis of myeloid cell location, behavior, and
gene expression within intact live tumors showed that the
functional heterogeneity of tumor-infiltrating myeloid
cells—macrophages in particular—may be greater than
anticipated by the analysis of static markers on fixed
tissues. In this regard, a recent study identified a distinct
macrophage subpopulation that mediates metastatic
cancer cell extravasation and pulmonary seeding in
mouse tumor models.64
Several recent reports have shown that both mouse
and human monocytes can be grouped into different
functional subsets. In murine blood, these include ‘inflam-
matory’ monocytes, which can give rise to several sub-
sets of macrophages (possibly including TAMs) and DCs
under inflammatory conditions; as well as ‘resident’
monocytes, which appear to patrol blood vessels and
promote tissue remodeling, and vascular healing, possi-
bly by differentiating toward tissue-resident proangio-
genic macrophages.20–22,65 One particular subset of cir-
culating monocytes, the Tie2-expressing monocytes
(TEMs), has been shown recently to play an important
role in tumor angiogenesis.5,6,37 TEMs express the an-
Figure 1. Various myeloid-lineage cell types implicated to date in the
regulation of tumor angiogenesis. Markers expressed (or not expressed) by
each of the distinct cell types are indicated. Note that several markers are
coexpressed by different myeloid cell types, raising the question of whether
some of these represent distinct cell types, rather then overlapping cell
subsets or differentiation states of a same cell type.
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giopoietin receptor Tie2,66 along with a wide array of
monocyte/macrophage markers. Another monocytic cell
type recently implicated in angiogenesis is the so-called
‘vascular leukocyte.’30 These cells, which are particularly
abundant in human ovarian tumors, coexpress monocyte
and EC markers, including Tie2, suggesting their close
relationship with TEMs.31
The developmental relationships among the distinct
monocyte subsets and tumor-infiltrating macrophages
are poorly defined (Figure 2). Monocytes are highly plas-
tic cells, and it is generally believed that their intratumoral
differentiation toward distinct macrophage subpopula-
tions is regulated by the contextual assortment of cyto-
kines, chemokines, and growth factors present in the
tumor microenvironment. For instance, interleukin (IL)-4,
IL-13, and IL-10 are thought to directly stimulate the
growth-promoting and proangiogenic functions of TAMs,
a process known as ‘alternative macrophage activation’
or ‘M2 polarization’ (reviewed in 24). However, it is also
possible that distinct monocyte subsets give rise to dis-
tinct macrophage subpopulations in tumors. In line with
this hypothesis, Pucci and coworkers25 suggested that
circulating inflammatory and resident monocytes might
give rise to two distinct F4/80 tumor macrophage sub-
populations, the CD11cMrc1Tie2 classic TAMs and
the CD11cMrc1Tie2 TEMs, respectively. This has
been inferred primarily by the observation that resident
monocytes isolated from the blood of tumor-free mice
display a gene expression profile that is more similar to
tumor-derived TEMs than classic TAMs, whereas inflam-
matory monocytes are more closely related to TAMs than
TEMs. These novel findings might suggest that distinct
monocyte subsets are precommitted to distinct fates in
the tumor microenvironment.25 Whether the different
monocyte/macrophage subsets found in tumors repre-
sent distinct lineages25 or more plastic differentiation
states,24 and whether they are related to each other by a
precursor-to-mature cell relationship, is the object of cur-
rent investigations.
Polymorphonuclear Cells
Granulocytes, neutrophils in particular, and mast cells
are regarded a key source of proangiogenic factors in
certain experimental tumors. An early study examining
the importance of MMP9 and VEGF-A in pancreatic tu-
mors of RIP1-Tag2 mice noted that inflammatory cells are
the main producers of these two proangiogenic mole-
cules in tumors.67 Neutrophils, together with monocytes/
macrophages, have since been identified as the pre-
dominant source of MMP9 and other proangiogenic
molecules in RIP1-Tag2 mice.12,13 Although neutrophils
are found in lower frequency than macrophages in RIP1-
Tag2 insulinomas, their elimination by means of anti–Gr-1
antibodies (which, however, also bind inflammatory
monocytes; see below) in this tumor model reduces the
levels of MMP9 in the tumors, which in turn inhibits the
association of VEGF with VEGF receptor-2 (VEGFR-2) on
ECs, thus suppressing angiogenesis. Interestingly, a re-
cent study showed that neutrophils can either express a
protumoral or antitumoral phenotype according to the
levels of transforming growth factor (TGF)- present in
the tumor.68 Indeed, TGF- blockade enhanced the re-
cruitment of neutrophils with cytotoxic properties and
inhibited the growth of transplanted tumors. Of note, the
specific depletion of these neutrophils by means of anti-
Ly6G antibodies rescued tumor growth. Thus, like
TAMs,24 neutrophils may sense the tumor microenviron-
ment and express different activation states, which de-
termine their protumoral versus antitumoral activity in tu-
mors. The antitumor activities of cytoxic neutrophils
include the expression of immuno-activating cytokines
and enhanced capability of killing tumor cells in vitro68; it
will be worth investigating whether these “cytotoxic” neu-
trophils also display enhanced expression of antiangio-
genic cytokines (or lower expression of proangiogenic
ones) as compared with their “normal” counterpart.
MDSCs, often referred to as ‘CD11bGr-1 cells,’ are
a heterogeneous population of myeloid cells that encom-
passes immature monocytes, granulocytes, DCs, and
their precursors. Their multifaceted function in tumors,
phenotype, and complexity has been recently re-
viewed.18,19,69 The defining characteristics of MDSCs are
largely based on their ability to suppress innate and
adaptive immunity and expression of CD11b and Gr-1,
whereas expression of other phenotypic markers by MD-
SCs varies because of their diversity and inclusion of
myeloid cells at various stages of differentiation. Recent
attempts at narrowing down specific subpopulations of
these cells conclude that this group of cells can be
divided into monocytic (mononuclear-MDSCs) and neu-
trophilic (polymorphonuclear-MDSCs) and DC subpopu-
lations, which express phenotypic markers characteristic
of each respective subset.70–73 There is also some evi-
dence indicating that these subsets may have different
functions in tumors,70 but the predominant phenotype
and differentiation status of these cells once they migrate
Figure 2. A schematic illustrating the possible relationships among mono-
cyte/macrophage subpopulations found in tumors. Tumor-infiltrating mac-
rophages are known to derive from circulating CCR2 inflammatory mono-
cytes; however, it remains to be investigated whether inflammatory
monocytes give raise to each of the distinct macrophage subpopulations
found in tumors. The contribution of CCR2–resident monocytes to tumor
macrophages is currently unknown. Dashed arrows indicate putative de-
velopmental relationships.
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into premalignant tissue and tumors is unclear and is
likely dependent on the tumor model and tumor type.
Although MDSCs are believed to promote tumor progres-
sion through immunosuppression and other mecha-
nisms, these cells (or subsets of them, such as neutro-
phils) may also influence angiogenesis15–17,69—an effect
mediated, at least in part, by their release of proangio-
genic factors. In this regard, Shojaei and coworkers16
found that tumor refractoriness to anti-VEGF therapy cor-
relates with the marked accumulation of CD11bGr-1
myeloid cells (possibly neutrophils) within certain mouse
tumors. This finding suggests that some tumors may
co-opt VEGF-independent proangiogenic programs that
are executed by the tumor-infiltrating myeloid cells.
Prokinecitin 2, also known as Bv8 (a VEGF-like proan-
giogenic factor), is upregulated in myeloid cells by
tumor-derived granulocyte colony-stimulating factor and
appears to be a major player in driving refractoriness (or
resistance) to anti-VEGF therapy.17 Yet, an immunosup-
pressive function has not been conclusively demon-
strated for the proangiogenic CD11bGr-1 cells, raising
the question of whether or not they can truly be referred
to as MDSCs.
A number of experimental animal models have shown
mast cells to be important for tumor angiogenesis.74 Mast
cells accumulate during the premalignant stages of tu-
mor progression and at the periphery of invasive tumors.
They have direct proangiogenic activity attributable to
their production of MMPs, particularly MMP-9, and secre-
tion of other proangiogenic molecules such as basic
fibroblast growth factor, VEGF, and IL-8. In addition, mast
cells indirectly stimulate angiogenesis by secreting mast
cell–specific serine proteases that activate pro-MMPs
and stimulate stromal fibroblasts to synthesize collag-
ens.36 Tumors grown in transgenic mice deficient in mast
cells exhibit delayed tumor vascularization and progres-
sion. For instance, premalignant angiogenesis is abated
in a mast cell–deficient skin tumor-prone K14-HPV trans-
genic mouse,10 as well as during pancreatic islet cell
carcinogenesis,11 melanoma progression,75 and adeno-
matous colon polyposis.76
BM Transplantation in the Study of Tumor
Angiogenesis
A number of studies have used myeloablative BMT to
investigate the role of BM-derived myeloid cell in tumor
angiogenesis. In the majority of such studies, transgenic
mice ubiquitously expressing the reporter gene (eg, GFP
or LacZ) are used as BM donors so the fate of their
BM-derived cells after BMT can readily be identified and
tracked in recipients. Such reports consistently docu-
ment the accumulation of gene-marked myeloid-lineage
BMDCs in tumors, but whether these cells represented
monocytes, macrophages, mast cells, neutrophils, or
other cell types (including hematopoietic progenitors)
has often been ignored or not assessed in detail. In some
studies, such gene-marking strategies have been com-
bined with the use of cell type–specific antibodies on
tumor sections in an attempt to identify distinct BMDC
subsets in tumors (Table 2).1,2,5,6,25 These have shown
the presence of macrophages, monocytes, and granulo-
cytes among the transplanted BM-derived cells in tu-
mors. It should be noted, however, that ubiquitously ex-
pressed transgenes (such as those regulated by the
Rosa26 locus or CMV/-actin promoter) may preclude the
correct identification of each of the different BMDC types
that are recruited to the tumor microenvironment. Indeed,
transgene-positive macrophages, which massively infil-
trate tumors, may mask the less abundant BMDC cell
types and also increase the likelihood of detecting arti-
factual marking of nontransgenic cell types in the tu-
mors.33 Mouse lines expressing transgenes under the
control of myeloid-specific transcription regulatory ele-
ments (reviewed in 77) have been used to specifically
label or deplete myeloid-lineage cells in mice. However,
while narrowing down the range of BMDCs that express
the transgene in blood and tumors, these transgenic
mice may not always provide adequate resolution of the
different myeloid BMDC types recruited to the tumors.
Indeed, many of the “myeloid-specific” promoters (eg,
the LysM, Csf1r, CD11c promoters) are broadly active
among myeloid-lineage cells.
Regardless of the precise identity of the cell types
involved, several reports have demonstrated the impor-
tance of BMDCs in tumor angiogenesis by transplanting
wild-type BM cells into angiogenesis defective and/or
tumor-resistant mice.1,5,6,38,42,55,78,79 In this setting,
donor-derived BMDCs were able to rescue, at least in
part, tumor angiogenesis and growth in the mutant mice.
Different mechanisms have been proposed that may ac-
count for the ability of BMDCs to rescue the genetically
hampered angiogenesis; these include the paracrine
support of angiogenesis (via the release of proangio-
genic factors) or the direct incorporation of the BMDCs in
the tumor vasculature—the latter mechanism likely rep-
resenting a very rare event.33 Coussens and coworkers
used a BMT strategy to demonstrate that the expression
of MMP9 by BMDCs is crucial for tumor angiogenesis
and progression in the K14-HPV skin tumor-prone
mice55—a finding confirmed by further BMT studies in
other mouse tumor models.1,2 Du and coworkers2 stud-
ied the recruitment of several BMDC types, including
EPCs, pericyte precursor cells, and distinct myeloid cell
subsets (CD11b or VEGFR-1 myeloid cells, F4/80
macrophages, and TEMs), to glioblastomas grown in-
tracranially in mice previously transplanted with GFP-
tagged BM cells. The authors found that glioblastomas
unable to express hypoxia inducible factor (HIF)-1 re-
cruit far fewer of these BMDCs and are severely impaired
in their angiogenic phenotype and growth capacity. In-
deed, in agreement with previous studies,80,81 HIF-1
expressed in the highly hypoxic glioblastomas up-regu-
lates the expression of both VEGF and stromal cell–
derived factor-1 (SDF-1, or CXCL12), which in turn pro-
mote the influx and retention of the various BMDCs in the
tumor microenvironment.2 Among the tumor-infiltrating
BMDCs, TEMs were found to be an important source of
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MMP9, possibly explaining why their impaired recruit-
ment in HIF-1–deficient tumors2 or genetic elimination
in wild-type tumors5 impair angiogenesis and tumor
growth. Chan and coworkers82 recently showed that
knockdown of prolyl hyroxylase 2 (PHD2)—a molecular
oxygen sensor and negative regulator of HIF- sub-
units—in human colon carcinoma xenografts increases
the number of tumor-associated CD45 and CD11b
cells and promotes angiogenesis. However, unlike the
findings of Du and coworkers,2 they found that BMDC
recruitment to tumors is HIF-independent. Indeed,
PHD2 deficiency up-regulated the expression of the
proangiogenic factors, IL-8, and angiogenin, in a NF-
B–dependent but HIF-independent manner; IL-8 and
angiogenin were found to be important both for the
recruitment of BMDCs and the direct stimulation of
angiogenesis.82 Regardless of precise mechanisms in-
volved, these studies2,82 highlight the important role of
tumor hypoxia for the recruitment of proangiogenic
BMDCs to the tumor microenvironment.
BMT studies performed in various mouse tumor mod-
els have shown that TEMs play a crucial role in tumor
angiogenesis.5,33,37,83 TEMs were originally identified in
the peripheral blood and tumors of mice transplanted
with BM-derived HS/PCs transduced ex vivo with a lenti-
viral vector expressing GFP from Tie2 promoter/enhancer
sequences. The generation of Tie2-GFP transgenic mice
further confirmed that TEMs constitutively circulate in the
mouse blood and preferentially extravasate in tumors and
regenerating tissues. Importantly, TEMs have also been
identified in human peripheral blood and cancer.31,26,27
When TEMs carrying a Tie2-driven suicide gene are
selectively eliminated after BMT into tumor-bearing
mice, tumor angiogenesis is inhibited and tumor
growth markedly slowed; of note, the specific TEM
elimination in tumor models does not affect the recruit-
ment of other BMDCs, such as TAMs and neutrophils,
to the tumors.5 TEMs differ from the bulk of F4/80
TAMs by their distinguishing gene signature and are
enriched for genes that regulate tissue remodeling and
angiogenesis.25
The BMT strategies described above show how the
angiogenic program in tumors can be heavily modu-
lated by the recruited BMDCs. However, BMT experi-
ments usually use total body irradiation to enable the
full engraftment of donor-derived cells in the recipient
mice. In this regard, Ahn and Brown have shown that
tissue irradiation may significantly affect the composi-
tion and proangiogenic activity of myeloid cell infil-
trates in such tissues.1 Indeed, preirradiation of tissue
before tumor cell inoculation enhances the recruitment
of subsets of BM-derived CD11b myelomonocytic
cells in the growing tumors. The enhanced recruitment
of these CD11b cells at the site of tissue irradiation
facilitates, or even rescues angiogenesis after radiation-
induced EC damage. Indeed, the authors showed that
newly recruited BMDCs represent the sole source of MMP9
in such irradiated tissues. In addition to the important role of
BMDC-mediated MMP9 release in tumor angiogenesis, this
study provides circumstantial evidence that tissue irradiation
may alter the physiological fluxes of BMDCs to tumors.
Two recent reports have investigated the recruitment
of BMDCs to the tumors of mice surgically joined by
parabiosis.43,44 In these experiments, a GFP-transgenic
mouse was surgically joined to a wild-type mouse to
create a shared circulation between the two mice. The
contribution of the circulating GFP-positive cells to tumor
angiogenesis in the wild-type mouse was then studied
without the need to myeloablate (ie, irradiate) the host
hematopoietic system. In both studies,43,44 a variety of
gene-marked BMDCs (mostly of the myelomonocytic lin-
eage) were observed in the perivascular areas of both
xenografted and spontaneous tumor models, with little
evidence, if any, for the incorporation of bona fide EPCs in
the tumor blood vessels. Although parabiotic mouse
models seem to confirm BMT studies, it remains a pos-
sibility that irradiation and subsequent BMT make tumor
angiogenesis more dependent on the paracrine support
provided by BMDCs than in nonirradiated hosts.
Phenotypic Markers Used to Identify
Proangiogenic Myeloid Cells in Tumors
As discussed above, to identify proangiogenic myeloid
cells in murine tumors, investigators have used morpho-
logical criteria, examination of reporter gene expression,
and/or assessment of various myeloid-related, phenotypic
markers (see Table 2).1,2,5,6,25 However, as shown in Table
3, the most common phenotypic markers used to date—
CD45, CD11b, CD11c, F4/80, Gr-1, Tie2, CXCR4 and
VEGFR-1—are expressed by more than one myeloid cell
type, making it difficult to distinguish one cell from another.
CD45 (leukocyte common antigen) is a transmem-
brane protein broadly expressed by hematopoietic-lin-
eage cells, including myeloid and lymphoid cells. CD11b
(also known as MAC-1) is generally regarded as only
expressed by myeloid cells. However, several reports
documented the expression of CD11b by lymphocyte
and NK cell subsets, depending on their activation
status.84
Together with CD11b, F4/80 is a cell surface glyco-
protein regularly used to identify murine TAMs.85 Although
broadly and robustly expressed by both tissue-resident
and tumor-infiltrating macrophages, F4/80 expression
level has been found to diminish with some forms of
macrophage activation.86 It is also expressed, albeit at
lower levels, by circulating monocytes,20,21 mononuclear-
MDSCs,70–73 subpopulations of DCs,87 and peripheral
blood eosinophils,88 so myeloid cells other than TAMs
may express this antigen in tumors.
Markers/antigens expressed by neutrophils alone have
proven extremely elusive. Ly6G is a surface molecule
expressed almost exclusively on neutrophils and their
precursors, and anti-Ly6G antibodies may thus provide a
specific means to deplete these cells in mice.89 Another
antibody used in many studies to identify or systemically
deplete neutrophils in mice is anti–Gr-1, which however
recognizes both Ly6C and Ly6G surface antigens. Thus,
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anti–Gr-1 antibodies not only bind Ly6G neutrophils and
their BM precursors, but also Ly6C inflammatory mono-
cytes,20,21 DCs, and T cell subsets.89 On the other hand,
tumor-infiltrating TEMs and their circulating precursors
are reported to be Gr-1–negative.5 As mentioned earlier,
Gr-1 has also been used to help identify murine MDSCs
(together with CD11b), so it cannot be used to distinguish
between neutrophils and MDSCs.
Many markers once regarded as EC-specific (eg,
VEGFR-1, Tie2, VE-Cadherin, and Sca-1) are also ex-
pressed by subsets of myeloid-lineage cells. VEGFR-1,
a receptor activated by both VEGF-A and placental
growth factor, is expressed by monocytes/macro-
phages and their progenitors in the hematopoietic sys-
tem.90–92 The expression of the angiopoietin receptor,
Tie2,66 has been reported on monocytes (TEMs),5 vas-
cular leukocytes,31 and eosinophils,93 but not neutro-
phils,5 mast cells,94 or MDSCs.70 Interestingly, vascu-
lar leukocytes have been shown to also express the
EC-specific adhesion molecule, VE-Cadherin.9,30 It
should be noted that Sca-1, which is often regarded as
only expressed by HS/PCs and ECs, is now known to
be more broadly expressed in the hematopoietic sys-
tem, as both myeloid and lymphoid cell subsets may
express this molecule. Similarly, the SDF-1 receptor
CXCR4 is broadly, albeit not uniformly, expressed by mu-
rine hematopoietic cells.36 Thus, CD11b-, F4/80-, Tie2-,
VEGFR-1-, and CXCR4-expressing myeloid cells, which
have been reported to be proangiogenic in tumors by sev-
eral studies,1,2,5,6,38 may well represent overlapping rather
than distinct cell subsets.
Additional studies are now required to better under-
stand the phenotypic and functional complexity of my-
elomonocytic cells found in tumors. As an example, Pucci
Table 2. A Summary of the Phenotypic Markers Used to Date to Determine the Contribution of BMDCs to Tumor Angiogenesis
in Selected Publications
Reference Mouse/tumor model used Experimental strategies (selected)
1 MT1A2 murine mammary carcinoma or
radiation-induced fibrosarcoma—in wild-
type mice, Mmp9/ mice, or Cd11b
promoter-driven diphtheria toxin receptor
(DTR)/GFP mice
Transplantation of Tie2-LacZ or GFP-positive
BM cells into pre-irradiated, tumor-bearing
mice. Transplantation of wild-type BM cells
into pre-irradiated, Mmp9/tumor-bearing
mice, also before treatment with zolendronic
acid to target MMP9-expressing CD11b
cells. Transplantation of Cd11b-DTR/GFP BM
cells into Mmp-9/ tumor-bearing mice
before treatment with diphtheria toxin
6 TS/A and N202 mammary carcinoma, B16
melanoma, and Lewis lung carcinoma
(LLC) cells inoculated into nude or
syngenic C57BL/6 mice
Transplantation of lentiviral vector-transduced
BM cells expressing GFP from Tie2 prom./
enh. or ubiquitous promoters (CMV; Pgk)—
into nude or immuno-competent tumor-
bearing mice. Transplantation of lentiviral
vector-transduced BM cells expressing
GFP and thymidine kinase from Tie2 prom./
enh. or ubiquitous promoter (Pgk)—before
ganciclovir treatment of tumor-bearing mice
to ablate TEMs or myeloid cells
5 Transgenic Tie2-GFP and Tie2-thymidine
kinase (tk) FVB mice inoculated with
N202 murine mammary cells; RIP1-Tag2
spontaneous insulinoma model; nude
mice bearing orthotopic U87 human
glioblastoma cells
Transplantation of Tie2-GFP–transduced BM
into RIP1-Tag2 or U87 glioma-bearing mice
Transplantation of Tie2-tk BM into N202
tumor-bearing FVB mice to ablate TEMs
Transplantation of Tie2-tk BM into glioma-
bearing nude mice to ablate TEMs
2 Rag1-deficient (Rag1ko) and Rag1ko/
Mmp9/ mice inoculated with wild-type
or HIF1-deficient murine glioblastoma
orthotopically
Transplantation of GFP-positive Rag1ko or
Rag1ko, Mmp9/ BM into Rag1ko or
Rag1ko, Mmp9/ glioma-bearing mice
25 Transgenic Tie2-GFP FVB mice inoculated
with N202 murine mammary cells; PyMT-
MMTV mammary tumor-prone mice
Transplantation of Tie2-GFP BM into
PyMT-MMTV tumor-bearing mice
Table continues
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et al recently compared gene expression in TEMs and
TAMs from murine tumors along with spleen-derived
CD11bGr-1 MDSCs. Although TEMs were highly re-
lated to TAMs (but not to MDSCs), several genes were
found to be differentially expressed in the two macro-
phage subpopulations, suggesting that TEMs represent
a distinct subset or differentiation state of TAMs. Among
these, Arginase1 (Arg1) and many scavenger receptors
were up-regulated, whereas Nos2 and many proinflam-
matory molecules were down-regulated in TEMs versus
TAMs (Table 2).1,2,5,6,25 These data have helped identify
a TEM surface marker profile (F4/80Gr-1Tie2Mrc1
CD11clow/CD163Lyve1TLR4Stab1), which distin-
guishes them from the bulk of TAMs (F4/80Gr-1low/
Tie2Mrc1low/CD11chighCD163low/Lyve1low/TLR4low/
Stab1low/). Moreover, the data have identified molecular
pathways that may account for the marked proangio-
genic and protumoral activity of TEMs and might be
targeted to block the activity of TEMs in tumors.25
Genome-wide expression profiling of the distinct my-
eloid cell types identified so far in tumors may unravel,
together with live imaging analysis,62 novel and/or cell-
type specific markers that better address their pheno-
typic and functional relationships.
Table 2. Continued
Phenotypic markers expressed by myeloid cells in tumors after bone marrow transplantation
Myeloid cell(s)
Identified CD45 CD11b F4/80 Tie2 Gr-1 CXCR4 VEGFR1 VEGFR2 CD34 Other markers
BM-derived
myelomonocytic
cell*
ND  ND ND  ND ND ND ND CD11c
Tie2 cell
(BM-derived,
non-endothelial
cell)
ND ND ND Tie2-LacZ ND ND ND ND ND CD31
TEM      ND ND  / CD31 Sca-1
Macrophage      ND ND ND  CD31 Sca-1
Granulocyte      ND ND ND ND ND
TEM      ND ND   c-Kit Sca-1
Macrophage      ND ND ND ND
Granulocyte  ND    ND ND  
Mesenchymal
progenitor
(non-BMDC)
     ND ND ND ND CD13, CD31, Sca-1,
c-Kit/, CD45
Macrophage  ND  ND ND ND ND ND ND CD31
Myeloid cell   ND ND ND ND ND ND ND CD31
TEM  ND ND  ND ND ND ND ND CD31
Hemangiocyte**  ND ND ND ND ND  ND ND CD31
BMDC***  ND ND ND ND  ND ND ND CD31
Pericyte progenitor
cell (PPC)
 /  ND ND ND ND ND ND CD31, PDGFR-,
Sca-1
TEM      ND ND ND ND CD163, Mrc1. TLR4,
IL-4ra/, Lyve1,
CD11c, CD31,
CD41, c-Kit, FcR1
TAM      ND ND ND ND CD11c, Lyve1, CD163/,
MRC1/, TLR4, CD31,
CD41, c-Kit
 indicates expressed/measured; , not expressed; ND, not determined; BMDC, bone marrow-derived cell; TEM, Tie2-expressing monocyte.
*Includes subset of Tie2-expressing cells (TEMs).
**The term “hemangiocyte” has been coined by Rafii and colleagues (Jin et al., Nat Med 2006) to indicate a type of myeloid precursor cell
expressing VEGFR1, CXCR4, Sca-1, and Tie2, in ischemic tissues.
***The expression of CXCR4 and VEGFR1 has been previously associated with MMP9 BMDCs recruited to heart and liver upon transgenic
overexpression of VEGF (Grunewald et al., Cell 2006).
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Relevance of BMDCs to Human Tumor
Angiogenesis
As mentioned earlier, a number of studies have reported
significant correlations between the number of various
myeloid cell types and microvessel density/angiogenesis
in human tumors (reviewed recently in 32). However,
similarities between the phenotype and function of the
human tumor-infiltrating myeloid cell types and the
proangiogenic BMDCs described earlier in mouse mod-
els have yet to be investigated. To date, human tumor
studies have focused on just individual or small combi-
nations of hematopoietic or myeloid cell markers. For
example, increased numbers of CD45 cells are associ-
ated with high microvessel density in some human tumor
types.95,96 CD11b myeloid cells have been shown to be
present in human tumors,27,97 but no studies to date have
correlated their number or function with human tumor an-
giogenesis. Moreover, the Ly6C and Ly6G antigens are
specific to the mouse, so the role of Gr-1 myeloid cells
cannot be assessed in human tumors.
TAMs are usually identified in human tumors by their
expression of CD6823,54 rather than F4/80. Indeed, the
human homolog of F4/80, the EGF-like module containing
mucin-like hormone receptor–1, is expressed by eosino-
phils rather than monocytes or macrophages.98 Elevated
numbers of CD68 TAMs have been correlated with in-
creased vascularization in human tumors.99 VEGFR-1 ex-
pression has also been reported on TAMs in tumors.100
Ruan and coworkers101 reported that aggressive human
lymphoma subtypes recruit more CD68VEGFR-1 my-
eloid cells than indolent lymphomas. The CD68VEGFR-1
cells were localized around tumor blood vessels, as well as
in the stromal compartment of the tumor; interestingly, these
cells expressed VEGF-A, suggesting that a paracrine
cross talk between myeloid cells and blood vessels
occurs in aggressive lymphomas. Macrophages also
express CXCR4 in human tumors and ascites fluid,102,103
whereas information regarding CXCR4 expression on other
myeloid cell types in tumors is lacking.
Monocytes/macrophages expressing CD14, CD11b,
and TIE2, likely corresponding to the human counterpart
of murine TEMs, have also been detected in human tumor
biopsies.31,27 The human TEMs represent a minor pro-
portion of the CD45 tumor-infiltrating hematopoietic
cells but appear to be highly proangiogenic as they
promote tumor angiogenesis when coinjected with hu-
man tumor cells in immunodeficient mice. Although TIE2
expression has been reported on human peripheral
blood neutrophils by some groups and not by oth-
ers,26,27,104 the existence of tumor-associated TIE2
neutrophils has yet to be reported. Detailed colocaliza-
tion studies are now warranted to see whether BMDCs
expressing all or most of the markers expressed by
proangiogenic BMDCs in murine tumors are present in
human tumors—and whether their presence, number, or
pattern of distribution positively correlates with tumor
angiogenesis. The use of human/mouse chimera ap-
proaches, such as the reconstitution of the BM of immu-
nodeficient mice with human HS/PCs, could provide an
experimental tool to investigate the contribution of human
BMDCs to angiogenesis in xenografted human tumors.
Whereas these mouse models can be used to track the
fate of transplanted human HS/PCs, they unfortunately
only allow for limited human myelopoiesis and thus may
fail to reliably assess the contribution of human myeloid
cells to tumor angiogenesis.
Concluding Remarks
The studies discussed above show that identification of
the distinct myeloid cell types responsible for driving
tumor angiogenesis remains a major challenge at the
present time. Not only do different myeloid cells exhibit
overlapping markers, but the exact level and combination
of these may alter as they differentiate and respond to
local signals in their tissue microenvironment. A classic
example of the latter is the heterogeneity of macrophage
phenotypes seen in tumors. This may either reflect the
existence of developmentally distinct subpopulations, or
the influence of signals in the tumor microenvironment
like hypoxia and/or various cytokines on a common
monocyte precursor (or the combination of both). More-
over, the balance of these influences may differ between
tumor types and indeed between tumors of a given type.
Table 3. Overlapping Expression of Phenotypic Markers/Antigens by Individual Myeloid Cell Types
Marker
Inflammatory
Monocyte
Resident
Monocyte TAM TEM
Dendritic
cell Mast cell Neutrophil Eosinophil MDSC
M H M H M H M H M H M H M H M H M H
CD45                  
CD11b                  
F4/80*            ND   ? ND / ND
CD11c /  /  /            / ND
Mrc1 /low ND  ND /low ND  ND ND ND    ND   ND ND
Tie2  /low low low     ND ND  ND  /  ND  ND
Gr1  X  X /low X  X low X  X  X  X  X
CXCR4       ND ND   ND       ND
VEGFR1† ND ND ND ND   ND ND          
M indicates mouse; H, human; , expression of antigen has been confirmed; low, expression of antigen low or limited to a fraction of the cells; ,
antigen not expressed /, positive expression reported by some investigators and negative expression by others; ND, not determined; X, antigen
does not exist for this species.
*The human homolog of murine F4/80 is known as “EGF-like module containing mucin-like hormone receptor (EMR)1.”
†VEGFR1 expression has been confirmed on monocytes, but it is not known whether expression levels are different between inflammatory and
resident subsets.
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The type and degree of myeloid cell infiltration into each
tumor may vary depending on the specific BM-mobilizing
and -recruiting factors released, as each tumor type
mounts its own protumorigenic microenvironment. In this
regard, it is generally believed that the type and concen-
tration of cytokines and growth factors expressed in the
tumor microenvironment may shape the phenotype and
function of TAMs. This concept is exemplified by the
macrophage polarization paradigm proposed by some
authors.23,24 According to this, TAMs are driven by cer-
tain tumor- and T cell–derived cytokines to acquire a
polarized “M2” phenotype, which favors tissue remodel-
ing, angiogenesis, and the suppression of antitumor
immunity. Similarly, tumor-derived factors such as
granulocyte colony-stimulating factor or TGF- may
drive neutrophils to acquire protumoral and proangio-
genic functions.13,17,68 This implies that neutralizing cer-
tain tumor-derived molecules may blunt the proangio-
genic and protumoral activities of macrophages and
neutrophils, possibly by skewing them toward and anti-
tumoral phenotype. On the other hand, recent studies
have suggested that, at least in certain murine tumors,
only a specific subset of the infiltrating macrophages, the
TEMs, display a profoundly “M2” skewed phenotype,
whereas another subset of TAMs retains features of an-
tigen-presenting cells and produces lower amounts of
proangiogenic factors.25 These findings also suggest
that distinct macrophage subpopulations (ie, the TEMs
and TAMs) may arise from distinct circulating precursor
cells.
Given the plethora of new studies uncovering such infor-
mation about the ontogeny and diversity of myeloid cells—
and how they are influenced by the tumor microenviron-
ment—it remains to be seen whether future studies using
cell markers alone will be able to unambiguously identify the
major cell type(s) involved. As discussed above, it may take
new approaches like the intravital imaging of myeloid cells
in live murine tumors to clarify their functions in relation to
the dynamic tumor microenvironment.62 Moreover, lineage-
specific cell-tracking studies are needed to investigate the
developmental relationships between BMDCs that traffic to
tumors. For instance, by genetic labeling and then following
of monocyte precursors, it may be possible to see whether
distinct monocyte/macrophage subpopulations, such as
the TEMs, TAMs, and “hemangiocytes,” are derived from a
single, circulating precursor cell or separate ones.
One outstanding question still needs to be addressed:
is it possible to identify molecular targets that could dis-
tinguish proangiogenic protumoral myeloid cells from the
antitumoral myeloid cells that regulate effective immune
responses against the tumor? If future studies identify
one or more cell surface proteins that are expressed by
all proangiogenic myeloid cells in tumors, it is possible
that they could be targeted by antibody-based or gene
therapeutic methods. Such a ‘broad-brush’ approach
may be important, as there is now evidence that selective
deletion of just one proangiogenic myeloid cell type (eg,
macrophages) from murine tumors may promote another
proangiogenic one (like neutrophils) to take on the role of
driving tumor angiogenesis.14,72 These strategies may
also have implications for the efficacy of conventional
therapies as such proangiogenic BMDCs have been im-
plicated in the responses of murine tumors to radiation or
chemotherapeutic agents.1,16,58 Alternatively, subpopu-
lations of such proangiogenic myeloid cells like TEMs
can be used to deliver gene therapy to sites of neovas-
cularization in tumors.105
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